recombinant human cd47 protein  (MedChemExpress)

Journal: Molecular Therapy. Nucleic Acids

Article Title: Nanoparticle-formulated mRNA encoding engineered multivalent SIRPα-Fc fusion proteins shows robust anti-cancer activity in preclinical models

doi: 10.1016/j.omtn.2025.102550

Figure Lengend Snippet: Binding characteristics of multivalent SIRPα molecules (A) The binding of serially titrated multivalent SIRPα molecules to CD47-expressing Raji and H9 cells was assessed by flow cytometry. Half-maximal effective concentration (EC50) values were calculated using a sigmoidal dose-response curve. This experiment is representative of three independent experiments. Error bars represent the standard deviation. (B) The binding of serially titrated multivalent SIRPα molecules was analyzed by ELISA by incubating with varying concentrations of CD47 antigen. This experiment is representative of two independent experiments.

Article Snippet: CD47 human recombinant proteins (0.5, 1, 2.5, and 5 μg/mL) were prepared in carbonate/bicarbonate buffer (Cat# 28382, Thermo Fisher) and plated.

Techniques: Binding Assay, Expressing, Flow Cytometry, Concentration Assay, Standard Deviation, Enzyme-linked Immunosorbent Assay